Vegovy Semaglutide Tablets.
Michael Siluk | Universal Images Group | getty images
Novo Nordisk on Tuesday launched a multi-month subscription program for its Vegovy obesity drug products, aimed at ensuring that patients paying cash get lower, “predictable” monthly prices.
Eligible patients can choose between a three, six or 12-month subscription to Wegovi injection or the two highest doses of the newly launched pill under the same brand name. According to the Novo release, the longer plans offer lower monthly pricing, and the company expects people will save up to $1,200 per year on the injection and $600 per year on the pill, relative to paying for their individual doses each month.
The company said patients can expect to pay the same monthly price, even if they switch to different doses. The membership program will be available starting Tuesday at several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and more. his and hersMore are expected to be added soon.
“The first-of-its-kind offering is an opportunity to help patients not only start treatment, but continue treatment and manage the ups and downs of some pricing considerations,” said Ed Cinca, head of marketing and patient solutions for Novo, “regardless of whether they are just starting treatment or are currently taking the drug.”
The inability to remain on GLP-1 due to factors such as difficulty accessing medications and gastrointestinal side effects is a long-standing problem. a 2025 study It is estimated that about 65% of patients with obesity discontinue treatment within a year.
Wegovi Membership Prices and Estimated Savings
injection subscription plans (0.25, 0.5, 1.7 and 2.4 mg dosages)
- 3-month: $329 per month, savings of $240 per year
- 6-months: $299 per month, saving $600 per year
- 12-month: $249 per month, savings of $1,200 per year
tablet subscription plans (9 and 25 mg dosage)
- 3-Month: $289 per month, saving $120 per year
- 6-months: $269 per month, saving $360 per year
- 12-month: $249 per month, savings of $600 per year
The new program also comes as Novo’s pill, which has seen explosive growth since its US launch in January, is set to face new competition from the upcoming oral GLP-1 from main rival. Eli Lilly later this year. Lilly is currently the dominant player in the branded GLP-1 market in the US with an estimated 60% share, while Novo has about 39%.
The Wegovi pill is reaching a large number of people who haven’t previously had a GLP-1 injection, making it important for Novo to capture as many new patients as possible before a competitor arrives.
As Novo Nordisk’s subscription plan launches, cash-paying patients can still pay $149 per month for the lower doses of the pill, which are 1.5 and 4 milligrams. But starting in August, a 4-milligram dose will cost $199 per month. Meanwhile, Wegovi’s recently approved 7.2-milligram dose will be added to the subscription program at a later date.
Cinca emphasized that if patients no longer wish to enroll, they can opt out of membership while it is still active.
“We want to help patients identify a pathway that can help them feel comfortable about treating (obesity) long-term,” he said.
Cinca said Novo is not yet offering the program on its NovoCare direct-to-consumer pharmacy, but he said there is an opportunity to “evaluate how that happens and then build it out” through that platform over time.
